Covance collaborates with French research institute
This article was originally published in Scrip
Covance, the French National Institute of Health and Medical Research subsidiary Inserm Transfert, and the seed investment company Inserm Transfert Initiative have signed a four-year scientific collaboration agreement for research and development.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"